Cempra Inc (NASDAQ:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be making a poster presentation at the European Respiratory Society (ERS) International Congress, being held in Amsterdam from September 26-30, 2015.
Presentation at ERS International Congress:
- A poster presentation will be made on Cempra’s Phase 3 clinical trial for oral solithromycin in which oral solithromycin was found to be non-inferior to and have a comparable safety and tolerability profile versus oral moxifloxacin for treatment of adult community acquired bacterial pneumonia (CABP). In elderly patients and those with COPD or asthma, compared to moxifloxacin, the number of responders on solithromycin was numerically greater. Late-Breaking Abstract (PA2655), Hall 14-29, Session 277, September 28, 12:50 p.m. CET.(Original Source)
Shares of Cempra closed yesterday at $36.07. CEMP has a 1-year high of $46.99 and a 1-year low of $9.67. The stock’s 50-day moving average is $36.09 and its 200-day moving average is $36.50.
On the ratings front, Cempra has been the subject of a number of recent research reports. In a report issued on September 9, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on CEMP, with a price target of $56, which represents a potential upside of 55.3% from where the stock is currently trading. Separately, on July 30, Needham’s Alan Carr reiterated a Buy rating on the stock and has a price target of $48.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Debjit Chattopadhyay and Alan Carr have a total average return of 24.6% and 32.8% respectively. Chattopadhyay has a success rate of 63.2% and is ranked #13 out of 3766 analysts, while Carr has a success rate of 66.0% and is ranked #7.
Cempra Inc is a clinical-stage pharmaceutical company. It develops antibiotics for acute care & community settings to meet critical medical needs in treatment of bacterial infectious diseases, respiratory tract & chronic staphylococcal infections.